The month of April was a bit lighter in quantity of hires, but those we did see were high-profile: pharma and biotech saw at least four CEO changes, as well as numerous board chairs.
For our final March hires roundup instalment, we have our “pharma-adjacent” roundup which includes CROs, clinical trial software companies, manufacturing organisations, suppliers, non-profi
Bristol-Myers Squibb’s long-serving chief executive Giovanni Caforio has said he will retire on 1st November after almost eight years in the role and more than two decades
March wasn’t the busiest month for big pharma shakeups, especially compared to the start of the year, but there was plenty of hustle and bustle at smaller pharma and biotech firms.